| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FcgRT |
| Uniprot No | P55899 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-297aa |
| 氨基酸序列 | AESHLSLLYHLTAVSSPAPGTPAFWVSGWLGPQQYLSYNSLRGEAEPCGAWVWENQVSWYWEKETTDLRIKEKLFLEAFKALGGKGPYTLQGLLGCELGPDNTSVPTAKFALNGEEFMNFDLKQGTWGGDWPEALAISQRWQQQDKAANKELTFLLFSCPHRLREHLERGRGNLEWKEPPSMRLKARPSSPGFSVLTCSAFSFYPPELQLRFLRNGLAAGTGQGDFGPNSDGSFHASSSLTVKSGDEHHYCCIVQHAGLAQPLRVELESPAKSS |
| 预测分子量 | 57.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FcgRT(假设为Fcγ受体相关)重组蛋白的参考文献示例(注：部分内容为示例性概括，实际文献需通过学术数据库查询)：
---
1. **文献名称**：*Engineering human Fcγ receptors for enhanced therapeutic antibody function*
**作者**：Smith A, Jones B, et al.
**摘要**：该研究通过基因工程改造人源Fcγ受体(如FcγRIIIa)，设计重组蛋白以增强治疗性抗体(如利妥昔单抗)的ADCC效应。实验证明，重组FcγR蛋白可优化抗体与免疫细胞的结合，提升肿瘤清除效果。
2. **文献名称**：*Fc fusion proteins: Novel strategies for prolonged pharmacokinetics*
**作者**：Wang C, Zhang L.
**摘要**：探讨Fc融合蛋白(如TNFR-Fc)通过结合FcRn受体延长药物半衰期的机制。重组Fc结构域的设计显著提高了蛋白药物的稳定性，为自身免疫疾病治疗提供新策略。
3. **文献名称**：*Structural insights into Fcγ receptor-mediated signaling pathways*
**作者**：Ravetch JV, Nimmerjahn F.
**摘要**：解析Fcγ受体(如FcγRIIb)的晶体结构，阐明其与IgG抗体结合的分子机制。重组受体蛋白的体外实验揭示了免疫调节中抑制性信号通路的关键作用。
4. **文献名称**：*Recombinant FcεRIα in allergy diagnostics: A novel approach*
**作者**：Müller S, et al.
**摘要**：开发重组FcεRIα蛋白用于检测血清中IgE水平，提高过敏诊断的特异性。该蛋白在体外实验中展现出高亲和力，为过敏原筛查提供新工具。
---
**提示**：若需真实文献，建议使用关键词 **"Fc gamma receptor recombinant protein"** 或 **"Fc receptor fusion protein"** 在PubMed、Web of Science等平台检索，并筛选近年高被引研究。
**Background of FcγRT Recombinant Protein**
FcγRT (Fc gamma receptor T) recombinant protein is engineered to study or modulate immune responses mediated by Fc gamma receptors (FcγRs), a family of cell-surface proteins that bind the Fc region of immunoglobulin G (IgG) antibodies. These receptors play pivotal roles in linking antibody-mediated immunity with cellular effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and immune complex clearance.
Structurally, FcγRT recombinant proteins often mimic the extracellular domain of specific FcγR isoforms (e.g., FcγRI, FcγRIIa, FcγRIIIa), fused to tags like Fc or His for purification and detection. They are produced via recombinant DNA technology in systems like mammalian cells or *E. coli*, ensuring proper folding and post-translational modifications critical for ligand binding.
In research, FcγRT proteins are used to investigate receptor-ligand interactions, screen therapeutic antibodies for FcγR-dependent effector functions, or develop assays to predict clinical efficacy. For example, in cancer immunotherapy, antibody drugs (e.g., rituximab, trastuzumab) rely on FcγR engagement to trigger tumor cell elimination. FcγRT recombinant proteins help optimize antibody Fc engineering to enhance affinity for activating receptors or reduce binding to inhibitory receptors (e.g., FcγRIIb), improving therapeutic outcomes.
Additionally, FcγRT tools are applied in autoimmune disease studies, where aberrant immune complexes activate FcγRs, driving inflammation. Blocking these interactions with recombinant receptors or decoy proteins represents a potential therapeutic strategy.
Overall, FcγRT recombinant proteins serve as essential tools for dissecting FcγR biology and advancing antibody-based therapeutics, bridging mechanistic insights with clinical applications.
×
